Wells Fargo analyst Tiago Fauth lowered the firm’s price target on Wave Life Sciences (WVE) to $18 from $21 and keeps an Overweight rating on the shares after the company reported AATD data update for 200 and 400 cohort. While the data support ‘006’s MoA, they do not clearly answer whether ‘006 can increase M-AAT levels to the 11microM+ threshold most investors were hoping for and potential positioning vs competitive landscape/modalities.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Why Is Wave Life Sciences Stock (WVE) Down 20% Today?
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Optimistic Buy Rating for Wave Life Sciences Driven by Promising RNA Editing Technology and Strong Safety Profile
- Wave Life Sciences price target raised to $26 from $24 at Leerink
- Beam competitive position intact after Wave data, says Clear Street